EA200701731A1 - Аэрозольные и впрыскиваемые рецептуры лекарственных препаратов бензодиазепина, состоящего из наночастиц - Google Patents

Аэрозольные и впрыскиваемые рецептуры лекарственных препаратов бензодиазепина, состоящего из наночастиц

Info

Publication number
EA200701731A1
EA200701731A1 EA200701731A EA200701731A EA200701731A1 EA 200701731 A1 EA200701731 A1 EA 200701731A1 EA 200701731 A EA200701731 A EA 200701731A EA 200701731 A EA200701731 A EA 200701731A EA 200701731 A1 EA200701731 A1 EA 200701731A1
Authority
EA
Eurasian Patent Office
Prior art keywords
formulations
nanoparticles
aerosol
benzodiazepin
recipes
Prior art date
Application number
EA200701731A
Other languages
English (en)
Other versions
EA013433B1 (ru
Inventor
Гэри Ливерсидж
Скотт Дженкинс
Original Assignee
Элан Фарма Интернэшнл Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Элан Фарма Интернэшнл Лтд. filed Critical Элан Фарма Интернэшнл Лтд.
Publication of EA200701731A1 publication Critical patent/EA200701731A1/ru
Publication of EA013433B1 publication Critical patent/EA013433B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Описаны рецептуры (композиции) бензодиазепина, состоящего из наночастиц, такого как лоразепам, которые не требуют присутствия полиэтиленгликоля и пропиленгликоля в качестве стабилизатора, а также способы получения и применения таких рецептур. Рецептуры особенно полезны в аэрозольной и инъекционной лекарственных формах и включают бензодиазепин, состоящий из наночастиц, такой как лоразепам, и по крайней мере один поверхностный стабилизатор. Рецептуры являются полезными для лечения эпилептического состояния, в качестве снотворного средства, при остром психозе, синдроме раздраженной толстой кишки и в качестве анестезирующего препарата.
EA200701731A 2005-02-15 2006-02-15 Аэрозольные и впрыскиваемые рецептуры лекарственных препаратов бензодиазепина, состоящего из наночастиц EA013433B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65303405P 2005-02-15 2005-02-15
PCT/US2006/005224 WO2006088894A2 (en) 2005-02-15 2006-02-15 Aerosol and injectable formulations of nanoparticulate benzodiazepine

Publications (2)

Publication Number Publication Date
EA200701731A1 true EA200701731A1 (ru) 2008-02-28
EA013433B1 EA013433B1 (ru) 2010-04-30

Family

ID=36781445

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200701731A EA013433B1 (ru) 2005-02-15 2006-02-15 Аэрозольные и впрыскиваемые рецептуры лекарственных препаратов бензодиазепина, состоящего из наночастиц

Country Status (14)

Country Link
US (2) US20060198896A1 (ru)
EP (3) EP1853234A2 (ru)
JP (1) JP2008530134A (ru)
KR (1) KR20070112164A (ru)
CN (1) CN101189001A (ru)
AU (1) AU2006214443C1 (ru)
BR (1) BRPI0608087A2 (ru)
CA (1) CA2597716A1 (ru)
EA (1) EA013433B1 (ru)
IL (1) IL185265A0 (ru)
MX (1) MX2007009915A (ru)
NO (1) NO20074602L (ru)
WO (1) WO2006088894A2 (ru)
ZA (1) ZA200707610B (ru)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060257324A1 (en) 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
GB2434152A (en) * 2006-01-16 2007-07-18 Whitford Plastics Ltd Fluoropolymer powdered materials
US20070281011A1 (en) 2006-05-30 2007-12-06 Elan Pharma International Ltd. Nanoparticulate posaconazole formulations
KR20170091770A (ko) 2006-07-10 2017-08-09 파이온 유케이 리미티드 속효형 벤조디아제핀 염 및 이의 중합체 형태
EP2101735A2 (en) * 2006-11-28 2009-09-23 Marinus Pharmaceuticals, Inc. Nanoparticulate formulations and methods for the making and use thereof
US20080275030A1 (en) 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
JP2008174495A (ja) * 2007-01-19 2008-07-31 Reverse Proteomics Research Institute Co Ltd 創薬標的タンパク質及び標的遺伝子、並びにスクリーニング方法
ES2594867T3 (es) 2007-03-09 2016-12-23 Alexza Pharmaceuticals, Inc. Unidad de calentamiento para usar en un dispositivo de administración de fármaco
JP2010526822A (ja) * 2007-05-07 2010-08-05 クエスター ファーマシューティカルズ，インク． ベンゾジアゼピン類の経鼻投与
US8530463B2 (en) * 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
WO2009046444A2 (en) * 2007-10-05 2009-04-09 Mdrna, Inc. Formulation for intranasal administration of diazepam
ES2586032T3 (es) 2008-03-28 2016-10-11 Hale Biopharma Ventures, Llc Administración de composiciones de benzodiazepinas
PL220269B1 (pl) * 2008-04-21 2015-09-30 Przedsiębiorstwo Produkcji Farmaceutycznej Hasco Lek Spółka Akcyjna Kompozytowy nośnik leków proszkowych, sposób wytwarzania nośnika leków oraz urządzenie do wytwarzania cząstek nośnika kompozytowego
WO2010074753A1 (en) 2008-12-23 2010-07-01 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
HUE032426T2 (en) * 2009-05-27 2017-09-28 Alkermes Pharma Ireland Ltd Inhibition of flake aggregation in nanoparticulate meloxicam formulations
US9012511B2 (en) 2010-05-19 2015-04-21 Alkermes Pharma Ireland Limited Nanoparticulate cinacalcet compositions
JP2013533310A (ja) * 2010-08-09 2013-08-22 ユニバーシティー オブ メリーランド，ボルティモア 苦味物質を使用して閉塞性肺疾患を処置する方法
EP2450039A1 (en) 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
CA2827336C (en) 2011-02-23 2016-01-26 Coeruleus Ltd. Flumazenil complexes, compositions comprising same and uses thereof
US20120288448A1 (en) * 2011-05-10 2012-11-15 Nwachukwu Chisomaga Ugochi Sprayable Compositions For Reducing Particulates In The Air
US10252210B2 (en) 2011-05-10 2019-04-09 The Procter & Gamble Company Methods for reducing particulates in the air
WO2012174158A2 (en) 2011-06-14 2012-12-20 Hale Biopharma Ventures, Llc Administration of benzodiazepine
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
CA2859209A1 (en) * 2011-12-20 2013-06-27 Map Pharmaceuticals, Inc. Excipient-free aerosol formulation
NZ627781A (en) 2012-01-23 2016-10-28 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
CA2869849A1 (en) * 2012-04-13 2013-10-17 Glaxosmithkline Intellectual Property Development Limited Aggregate particles comprising nanoparticulate drug particles of umeclidinium bromide, vilanterol trifenatate and fluticasone furoate
UA115063C2 (uk) * 2012-05-22 2017-09-11 ПАЙОН ЮКей ЛІМІТЕД Композиції, які містять бензодіазепіни короткої дії
US9125805B2 (en) * 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
US20140050789A1 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
IL275725B (en) 2012-08-21 2022-08-01 Sage Therapeutics Inc Treatment methods for epilepsy and status epilepticus
JP2015227288A (ja) * 2012-08-31 2015-12-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 けいれん重積発作の治療用医薬組成物
WO2014085668A1 (en) 2012-11-30 2014-06-05 The Regents Of The University Of California Anticonvulsant activity of steroids
CN105007898A (zh) * 2012-12-19 2015-10-28 卡希夫制药有限责任公司 难溶性药物的过饱和的稳定纳米颗粒
US8999393B1 (en) * 2013-01-09 2015-04-07 Edgemont Pharmaceuticals Llc Sustained release formulations of lorazepam
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
KR102408399B1 (ko) 2016-03-08 2022-06-13 세이지 테라퓨틱스, 인크. 신경활성 스테로이드, 조성물, 및 그의 용도
CA3046385C (en) * 2016-12-09 2023-12-19 Alexza Pharmaceuticals, Inc. Treatment of seizure or epilepsy using alprazolam in the form of a condensation aerosol
CN107007559B (zh) * 2017-04-21 2020-05-15 浙江京新药业股份有限公司 一种稳定的口服药物组合物及其制备方法
CN109846841B (zh) * 2019-01-18 2021-06-01 西安力邦医药科技有限责任公司 一种速效氯巴占口服冻干制剂及其制备方法
KR20200090359A (ko) * 2019-01-21 2020-07-29 크리스탈지노믹스(주) Fab I 저해제를 포함하는 주사제용 조성물 및 그 제조방법
WO2020164008A1 (en) 2019-02-13 2020-08-20 Bayer Aktiengesellschaft Process for the preparation of porous microparticles
JP7337363B2 (ja) * 2019-02-28 2023-09-04 株式会社ウェルナス 睡眠を改善するための経口摂取用組成物
IL294521A (en) * 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses
CN114177135B (zh) * 2022-01-04 2022-11-15 朗天药业(湖北)有限公司 帕拉米韦药物组合物及其制备方法

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3207178A (en) * 1963-01-04 1965-09-21 Ohio Brass Co Combination motor control valve and exhaust flow control
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
SU628930A1 (ru) 1974-11-26 1978-10-25 Московский научно-исследовательский институт туберкулеза Устройство дл введени порошкообразного лекарственного вещества
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
GB8413191D0 (en) * 1984-05-23 1984-06-27 Beecham Group Plc Pharmaceutical composition
US4783484A (en) 1984-10-05 1988-11-08 University Of Rochester Particulate composition and use thereof as antimicrobial agent
FR2575678B1 (fr) * 1985-01-04 1988-06-03 Saint Gobain Vitrage Ejecteur pneumatique de poudre
JP2573275B2 (ja) * 1986-03-10 1997-01-22 ブルグハルト，クルト 薬学的製剤及びその製造法
IT1217890B (it) 1988-06-22 1990-03-30 Chiesi Farma Spa Dispositivo per l'inalazione di aerosol dosati
US5068858A (en) * 1989-12-21 1991-11-26 International Business Machines Corporation Error correction capability varied with track location on a magnetic or optical disk
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5552160A (en) * 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
AU642066B2 (en) 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
CA2112905A1 (en) * 1991-07-05 1993-01-21 Michael R. Violante Ultrasmall non-aggregated porous particles entrapping gas-bubbles
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
AU660852B2 (en) 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5349957A (en) 1992-12-02 1994-09-27 Sterling Winthrop Inc. Preparation and magnetic properties of very small magnetite-dextran particles
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5302401A (en) * 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5401492A (en) 1992-12-17 1995-03-28 Sterling Winthrop, Inc. Water insoluble non-magnetic manganese particles as magnetic resonance contract enhancement agents
US5326552A (en) 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
US5885486A (en) * 1993-03-05 1999-03-23 Pharmaciaand Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
US5264610A (en) * 1993-03-29 1993-11-23 Sterling Winthrop Inc. Iodinated aromatic propanedioates
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5718388A (en) * 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
US6692766B1 (en) 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
US5525328A (en) 1994-06-24 1996-06-11 Nanosystems L.L.C. Nanoparticulate diagnostic diatrizoxy ester X-ray contrast agents for blood pool and lymphatic system imaging
US5587143A (en) 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US5628981A (en) 1994-12-30 1997-05-13 Nano Systems L.L.C. Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
US5585108A (en) 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5466440A (en) * 1994-12-30 1995-11-14 Eastman Kodak Company Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays
US5560932A (en) * 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5569448A (en) 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5571536A (en) * 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5560931A (en) * 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5593657A (en) 1995-02-09 1997-01-14 Nanosystems L.L.C. Barium salt formulations stabilized by non-ionic and anionic stabilizers
US5518738A (en) 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5622938A (en) 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5591456A (en) 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5500204A (en) * 1995-02-10 1996-03-19 Eastman Kodak Company Nanoparticulate diagnostic dimers as x-ray contrast agents for blood pool and lymphatic system imaging
US5573783A (en) 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5543133A (en) 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5565188A (en) 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5718919A (en) * 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
US5747001A (en) * 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
JP4484247B2 (ja) 1995-02-24 2010-06-16 エラン ファーマ インターナショナル，リミティド ナノ粒子分散体を含有するエアロゾル
US5643552A (en) 1995-03-09 1997-07-01 Nanosystems L.L.C. Nanoparticulate diagnostic mixed carbonic anhydrides as x-ray contrast agents for blood pool and lymphatic system imaging
US5573749A (en) 1995-03-09 1996-11-12 Nano Systems L.L.C. Nanoparticulate diagnostic mixed carboxylic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging
US5472683A (en) 1995-03-09 1995-12-05 Eastman Kodak Company Nanoparticulate diagnostic mixed carbamic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging
US5521218A (en) 1995-05-15 1996-05-28 Nanosystems L.L.C. Nanoparticulate iodipamide derivatives for use as x-ray contrast agents
US5573750A (en) 1995-05-22 1996-11-12 Nanosystems L.L.C. Diagnostic imaging x-ray contrast agents
US5834025A (en) 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
WO1998035666A1 (en) * 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
US6699849B1 (en) 1998-02-23 2004-03-02 Cyclops, Ehf. Cyclodextrin complexes of benzodiazepines
US6153225A (en) 1998-08-13 2000-11-28 Elan Pharma International Limited Injectable formulations of nanoparticulate naproxen
US6165506A (en) 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US6375986B1 (en) 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6428814B1 (en) 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6270806B1 (en) 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
US6267989B1 (en) 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
CA2393195C (en) * 1999-06-01 2007-02-20 Elan Pharma International Limited Small-scale mill and method thereof
US20010031475A1 (en) * 2000-02-23 2001-10-18 Gallop Mark A. Self-encoded combinatorial synthesis of compound multiplets
US6582285B2 (en) * 2000-04-26 2003-06-24 Elan Pharmainternational Ltd Apparatus for sanitary wet milling
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6372919B1 (en) * 2001-01-11 2002-04-16 Dov Pharmaceutical, Inc. (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as an anti-depressant agent
JP2004517699A (ja) * 2001-01-30 2004-06-17 ボード オブ リージェンツ ユニバーシティ オブ テキサス システム 液体中への噴霧凍結によるナノ粒子およびミクロ粒子の製造方法
WO2002094218A2 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
US6805853B2 (en) * 2001-11-09 2004-10-19 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
AU2002312230A1 (en) 2001-06-05 2002-12-16 Elan Pharma International Limited System and method for milling materials
FR2830017B1 (fr) * 2001-09-27 2005-11-04 Centre Nat Rech Scient Materiau compose d'au moins un polymere biodegradable et de cyclodextrines
WO2003030872A2 (en) * 2001-10-12 2003-04-17 Elan Pharma International Ltd. Compositions having a combination of particles for immediate release and for controlled release
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
UA76810C2 (ru) * 2001-12-10 2006-09-15 Мерк Енд Ко., Інк. Фармацевтическая композиция антагониста рецептора тахикинина в форме наночастиц
EP1319423A3 (en) * 2001-12-11 2003-10-08 Dornier Medtech System GmbH Apparatus and method for initiating chemical reactions and for the targeted delivery of drugs or other agents
US7029918B2 (en) * 2002-01-25 2006-04-18 Roche Diagnostics Operations, Inc. Water-soluble derivatives of lipophilic drugs
EP1511468A1 (en) * 2002-06-10 2005-03-09 Elan Pharma International Limited Nanoparticulate sterol formulations and sterol combinations
WO2004004702A2 (en) * 2002-07-09 2004-01-15 The Scripps Research Institute Method to inhibit ischemia and reperfusion injury
US20040258757A1 (en) * 2002-07-16 2004-12-23 Elan Pharma International, Ltd. Liquid dosage compositions of stable nanoparticulate active agents
DE60309731T2 (de) * 2002-08-21 2007-06-28 Pharmacia Corp. Injizierbare pharmazeutische suspension in einer phiole mit zwei kammern
US7713551B2 (en) * 2002-09-11 2010-05-11 Elan Pharma International Ltd. Gel stabilized nanoparticulate active agent compositions
WO2004032980A1 (en) * 2002-10-04 2004-04-22 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
AU2003297151A1 (en) * 2002-12-17 2004-07-22 Elan Pharma International Ltd. Milling microgram quantities of nanoparticulate candidate compounds
US20060178354A1 (en) * 2003-02-27 2006-08-10 Lucas John M Methods and compositions for the treatment of chronic pain using dhea and derivatives thereof
US20050031688A1 (en) * 2003-08-04 2005-02-10 Ayala William J. Positive wakeup pharmaceutical sleep system with compatible pre-bedtime administration
US20050031713A1 (en) * 2003-08-06 2005-02-10 Elliot Ehrich Methods for administering active agents to CYP3A4 sensitive patients
US20050031544A1 (en) * 2003-08-07 2005-02-10 Njemanze Philip Chidi Receptor mediated nanoscale copolymer assemblies for diagnostic imaging and therapeutic management of hyperlipidemia and infectious diseases
CA2534924A1 (en) * 2003-08-08 2005-02-24 Elan Pharma International Ltd. Novel metaxalone compositions
GB0319797D0 (en) * 2003-08-26 2003-09-24 Leuven K U Res & Dev Particle size reduction of poorly soluble drugs
US9149440B2 (en) * 2003-09-02 2015-10-06 University Of South Florida Nanoparticles for drug-delivery
WO2005044234A2 (en) * 2003-11-05 2005-05-19 Elan Pharma International Ltd. Nanoparticulate compositions having a peptide as a surface stabilizer
US20050147664A1 (en) * 2003-11-13 2005-07-07 Elan Pharma International Ltd. Compositions comprising antibodies and methods of using the same for targeting nanoparticulate active agent delivery
KR20070007276A (ko) * 2003-12-29 2007-01-15 제이슨 맥데빗 재발성 의학적 증상을 치료하기 위한 조성물 및 방법
EP1740179A1 (en) * 2004-04-20 2007-01-10 Pfizer Limited Method of treating neuropathic pain using a crth2 receptor antagonist
US20070184076A1 (en) * 2006-02-07 2007-08-09 Unger Evan C Liquid-filled nanodroplets for anti-cancer therapy

Also Published As

Publication number Publication date
US20090304801A1 (en) 2009-12-10
EP1853234A2 (en) 2007-11-14
WO2006088894A3 (en) 2006-11-30
AU2006214443C1 (en) 2011-11-24
KR20070112164A (ko) 2007-11-22
EP2332524A1 (en) 2011-06-15
US20060198896A1 (en) 2006-09-07
IL185265A0 (en) 2008-06-05
CN101189001A (zh) 2008-05-28
AU2006214443B2 (en) 2011-06-16
WO2006088894A2 (en) 2006-08-24
AU2006214443A1 (en) 2006-08-24
EP2353590A1 (en) 2011-08-10
CA2597716A1 (en) 2006-08-24
ZA200707610B (en) 2008-11-26
BRPI0608087A2 (pt) 2009-11-10
EA013433B1 (ru) 2010-04-30
MX2007009915A (es) 2007-11-06
NO20074602L (no) 2007-10-31
JP2008530134A (ja) 2008-08-07

Similar Documents

Publication Publication Date Title
EA200701731A1 (ru) Аэрозольные и впрыскиваемые рецептуры лекарственных препаратов бензодиазепина, состоящего из наночастиц
IL260127B (en) mek inhibitors and methods of using them
NO20063429L (no) Brusende oral opiat doseringsform
CY1114148T1 (el) Γεφυρωμενες δικυκλικες αρυλο- και γεφυρωμενες δικυκλικες etepoapyλo-υποκατεστημενες τριαζολες χρησιμες ως αναστολεις toy axl
WO2006138608A3 (en) Pharmaceutical compositions and use thereof
ECSP034438A (es) Nuevos peptidos como inhibidores de ns-3-serina proteasa del virus de la hepatitis c
IN2012DN02702A (ru)
CY1113421T1 (el) Πυρηνικα οξεα και πολυπεπτιδια υποδοχεα
WO2005084296A3 (en) Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogernase 3
MX2011007065A (es) Analogos de dicetopiperazina substituida para usarse como agentes de suministro de farmaco.
WO2005019247A3 (en) Cyclic peptide and imaging compound compositions and uses for targeted imaging and therapy
DK1654253T3 (da) Substituerede 3-pyrrolidinindolderivater
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
EA200700403A1 (ru) ТРИЦИКЛИЧЕСКИЕ δ-ОПИОИДНЫЕ МОДУЛЯТОРЫ
DE602005027728D1 (de) Benzodiazepin-Derivate als ROCK-Kinasen Hemmer
EA201071307A1 (ru) Карбамоильные производные бициклических карбониламинопиразолов в качестве пролекарств
ATE475408T1 (de) Formulierungen von tipifarnib zur intravenösen verabreichung
ATE342264T1 (de) Indolderivate und deren verwendung als gnrh antagonisten
AR039232A1 (es) Una formulacion farmaceutica que comprende al menos un compuesto seleccionado del grupo formado por hipnoticos no barbituricos y no benzodiacepinicos, y melatonina
ATE408619T1 (de) Lh-rh-antagonisten, deren herstellung und verwendung als arzneimittel
DE60319802D1 (de) Sedierende nicht-benzodiazepin-formulierungen
PL1668027T3 (pl) Cykliczne peptydy działające jako antagoniści Urotensyny-II
ZA200605653B (en) Proline derivatives used as pharmaceutical active ingredients for the treatment of tumours
CY1117211T1 (el) Νευροπροστατευτικες δικυκλικες ενωσεις και φαρμακευτικες συνθεσεις που τις περιεχουν
DE502006009398D1 (de) Substituierte benzokondensierte cycloheptanon-derivate und deren verwendung zur herstellung von arzneimitteln

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU